Executive Summary
JPM 2026 delivered a clear message: capital is back but selective. Execution replaced storytelling as the dominant theme, with management teams emphasizing launch curves and capacity.
Oral obesity pill orforglipron expected Q2 2026 FDA decision. Fast-track review secured.
"All in on obesity." Plans to initiate 10 Phase 3 trials by end of 2026 for Metsera assets.
Keytruda LOE protection. Revolution Medicines acquisition talks anchor oncology pipeline.
Methodology Note
This intelligence layer was compiled from primary conference coverage (FierceBiotech, FiercePharma, STAT News, BioPharma Dive, Endpoints News), company press releases, SEC filings, and attributed sell-side commentary. Rumors are explicitly labeled. Data validated across multiple sources where possible. Content reflects information available through January 15, 2026.